The company will advance dermatological treatments focusing on conditions such as atopic dermatitis. Credit: Andrey_Popov / Shutterstock.com.
Alys Pharmaceuticals has announced its launch with a research and development (R&D) immuno-dermatology focused pipeline backed by a $100m financing from Medicxi.
Co-founded by Medicxi and a team of dermatology and scientific specialists, Alys Pharmaceuticals is led by co-founder and COO Thibaud Portal, with Medicxi’s Francesco De Rubertis serving as board chairman.
The company’s pipeline is powered by multiple platform technologies, targeting a range of dermatological ailments.
Alys Pharmaceuticals’ pipeline also includes programmes for less common ailments such as mastocytosis and cutaneous T-cell lymphoma, and therapies to prevent skin side effects from cancer treatments.
See Also:Innovate UK grants funds for breast cancer therapy project
With 14 programmes at an active stage, Alys Pharmaceuticals anticipates significant growth from its new platforms, which cover inflammatory conditions, autoimmune ailments and supportive dermatological care for patients with cancer and rare dermatoses.
The company aims to achieve seven to ten clinical proof-of-concept readouts and advance at least one programme to registrational clinical trials in the coming three years.
Medicxi partner and Alys Pharmaceuticals chairman Francesco De Rubertis stated: “We believe that bringing together several asset-centric companies with a phenomenal team will power up Alys to transform innovation in immuno-dermatology.
“Alys manages a broad pipeline of assets with diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital.”